Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides

Conditions:   Mycosis Fungoides;   Sezary Syndrome;   Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage III Myco sis Fungoides and Sezary Syndrome AJCC v8;   Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IVA2 M ycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8 Intervention:   Biological: Pembrolizumab Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials